MedTrace Logo

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

NCT01571388 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-12-18

No results posted yet for this study

Summary

The study will determine if there are differences in how dacomitinib is absorbed and eliminated between healthy subjects and subjects with mild and moderately impaired hepatic function.

Conditions

  • Healthy
  • Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction

Interventions

DRUG

dacomitinib

Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

DRUG

dacomitinib

Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

DRUG

dacomitinib

Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01571388 on ClinicalTrials.gov